New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
09:15 EDTCLVS, OPHT, ACXM, URBN, SPLS, LIVE, DNDN, GPK, TJX, ICPT, CAB, MRK, IRDM, NVS, CCL, ARX, ODP, DKS, ECYTOn The Fly: Pre-market Movers
HIGHER: Aeroflex (ARX), up 25% after agreeing to be acquired by Cobham for about $1.46B... Clovis (CLVS), up 6.6% after receiving breakthrough therapy designation for CO-1686... Ophthotech (OPHT), up 17.6% after entering into an ex-U.S. licensing, commercialization agreement with Novartis (NVS) for Fovista... Dendreon (DNDN), up 9% after announcing presentation of PROVENGE ProACT, IMPACT studies data... Iridium (IRDM), up 5% after upgraded at Raymond James... Acxiom (ACXM), up 3% after upgraded at Wells Fargo... Carnival (CCL), up 2% following upgrade at Morgan Stanley. DOWN AFTER EARNINGS: Dick's Sporting (DKS), down 15%. Peer Cabelas (CAB) also down 2% after Dick's report... Staples (SPLS), down 10%. Peer Office Depot (ODP) also down 2.6% after Staples' report... Urban Outfitters (URBN), down 4%... TJX (TJX), down 4.7%. ALSO LOWER: Intercept (ICPT), down 5.8% after The Street reported that the company knew of abnormal cholesterol levels in patients taking its liver disease drug obeticholic acid... Graphic Packaging (GPK), down 3% after offering 43.65M shares of common stock for holders... LiveDeal (LIVE), down 15% after entering 10M share common stock distribution agreement... Endocyte (ECYT), down 5% after company and partner Merck (MRK) withdraw CMA for vintafolide in Europe.... Molycorp (MCP), down 2.5% after downgraded at Morgan Stanley.
News For DKS;CAB;SPLS;ODP;ICPT;URBN;ARX;TJX;ACXM;CCL;GPK;OPHT;NVS;DNDN;CLVS;IRDM;LIVE;ECYT;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 23, 2015
08:19 EDTGPKBofA/Merrill paper/forest products analyst hold analyst/industry conference call
Subscribe for More Information
08:10 EDTNVSArray agrees to acquire rights to encorafenib
Array BioPharma (ARRY) announced that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015. Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib. As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights. Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit. At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array's full time equivalent costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period. For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array's FTE costs in connection with completing the trials. Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib. Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction. In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.
07:36 EDTNVSIncyte earns $25M milestone payment from Novartis for Jakavi
Subscribe for More Information
07:25 EDTNVSNovartis drug Jakavi recommended by CHMP for EU approval
Subscribe for More Information
06:39 EDTMRKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 22, 2015
08:38 EDTLIVELiveDeal to advertise at NHL All-Star League
Subscribe for More Information
07:17 EDTICPTIntercept price target lowered to $300 from $500 at Deutsche Bank
Subscribe for More Information
January 21, 2015
12:35 EDTNVSNovartis confirms FDA approval for Cosentyx
Subscribe for More Information
12:33 EDTNVSFDA approves Novartis psoriasis drug Cosentyx
Subscribe for More Information
10:26 EDTNVSHigh option volume stocks
Subscribe for More Information
10:16 EDTMRKLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
08:02 EDTMRKMerck completes tender offer to acquire Cubist
Merck (MRK) announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals (CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7% of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares. Following consummation of the tender offer, Merck expects to complete the acquisition of Cubist later today through a merger of Merckís wholly owned subsidiary with and into Cubist without stockholder approval. Upon completion of the merger, all outstanding shares of common stock of Cubist, other than shares held by Cubist in treasury or shares held by Cubistís stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $102.00 offer price per share without interest, less any applicable withholding taxes. In addition, upon completion of the merger, Cubist will become a wholly owned subsidiary of Merck and the common stock of Cubist will cease to be traded on the NASDAQ Stock Market.
January 20, 2015
17:18 EDTMRKDana Holding to replace Cubist in S&P 400 as of 1/22 close
Subscribe for More Information
13:09 EDTSPLS, ODPSources: Staples to spurn Starboard's call to merge with Office Depot, FT says
Subscribe for More Information
10:47 EDTODP, SPLSStaples says will consider 'all actions' that would create shareholder value
Subscribe for More Information
10:23 EDTODP, SPLSStarboard says Staples should explore merger with Office Depot
Starboard Value, one of the largest shareholders of Staples (SPLS), confirmed, as previously reported, that it has delivered a letter to Ronald Sargent, Chairman and CEO of Staples, and the board of directors of Staples. In the letter, Starboard states in part: "As we discussed in our recent meeting, we believe that the best way to maximize value for Staples' shareholders is through exploring and completing a business combination with Office Depot (ODP). For a variety of reasons, we believe that now is the right time to pursue such a transaction, and we urge you to immediately retain a reputable investment bank and legal advisors to assist the Board in evaluating, structuring and executing a transaction with Office Depot. We believe that a strategic combination of Staples and Office Depot would result in synergies that would more than double the operating profits of the combined company and would create an industry-leading office supply retailer that could more effectively compete against larger retailers and online competitors. The magnitude of value creation from such a business combination far exceeds anything that either company could achieve on a standalone basis. We believe that the evidence is clear that shareholders are broadly supportive of a transaction between Staples and Office Depot. As shown in the chart below, since the merger speculation began last September, Staples' share price has risen over 50%, strongly outperforming the S&P 500...After the recent increase in Staples' share price, we believe the stock now trades at a substantial premium to the intrinsic value of the standalone company. This results in a lower cost of capital for Staples and a stronger currency which could be used to acquire Office Depot. If Staples fails to fully explore and consummate a transaction with Office Depot, shareholders will undoubtedly be extremely disappointed...We understand that this will require cooperation from Office Depot, and we have already expressed to them our strong support for a transaction...Our sincere hope is that we can continue to have a constructive dialogue. However, if it becomes clear to us that you have no intention of seriously pursuing this unique and highly attractive opportunity, it would be a clear sign that significant leadership change is needed at Staples."
09:31 EDTODP, SPLSActivist Starboard urging Staples, Office Depot to merge, WSJ reports
Subscribe for More Information
09:08 EDTLIVELiveDeal expanding ad campaign to sports venues and events
Subscribe for More Information
08:59 EDTSPLS, ODPStarboard urged Staples to explore Office Depot merger, Bloomberg says
Subscribe for More Information
07:23 EDTMRKMerck funding testing of lower dosages of Zilmax, Reuters reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use